Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

Related Keywords

Taiwan ,United States ,Kwangdong ,Ch Ungch Ong Bukto ,South Korea ,China ,Macau ,Hong Kong ,Hainan Province ,Hainan ,Republic Of Korea ,South Korean ,American ,Chinese ,Carl Spana ,Fosun Pharma ,Korean Ministry Of Food Drug Safety ,Drug Administration ,Kwangdong Pharmaceuticals ,Palatin Technologies Inc ,Prnewswire Palatin Technologies Inc ,Exchange Commission ,Securities Exchange ,Chinese National Medical Products Administration ,Chinese Hainan ,Hypoactive Sexual Desire Disorder ,Korean Ministry ,Drug Safety ,Chief Executive Officer ,Hainan Free Trade Zone ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Palatin Technologies ,Nc ,